Class IIReported 2025-11-12

Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.

Recalled by Teva Pharmaceuticals USA, Inc

Reason for Recall

Subpotent drug; Clavulanate Potassium component

Recall Number

D-0151-2026

Classification

Class II

Status

Ongoing

Category

drug

Initiated

2025-10-13

Reported

2025-11-12

Distribution

Distributed in three (3) States: MS, OH, CA.

Code Info

Lot # 100062316, Exp Date: 01/2026

Source: openFDA enforcement report. WhichRecall is not affiliated with the FDA. See our disclaimer.